{"result": "{\n    \"title\": \"TRYPHAENA and HER2+ Inflammatory Breast Cancer Community\",\n    \"summary\": \"The community revolves around TRYPHAENA, a clinical trial investigating the safety and tolerability of dual anti-HER2 antibodies with different regimens. The trial has relationships with various chemotherapy treatment protocols, authors, and cardiac safety studies, all of which are associated with HER2+ Inflammatory Breast Cancer (IBC).\",\n    \"rating\": 7.0,\n    \"rating_explanation\": \"The impact severity rating is moderate due to the potential for significant medical advancements and implications for patients with HER2+ IBC.\",\n    \"findings\": [\n        {\n            \"summary\": \"TRYPHAENA as a key clinical trial\",\n            \"explanation\": \"TRYPHAENA is a comprehensive clinical trial that investigated the safety and tolerability of dual anti-HER2 antibodies with different regimens. The trial's findings have significant implications for the treatment of HER2+ IBC. [Data: Entities (166), Relationships (212, 210, 209, 211, 214, 217, 216, 215, 213, 218)]\"\n        },\n        {\n            \"summary\": \"Chemotherapy treatment protocols\",\n            \"explanation\": \"The community includes various chemotherapy treatment protocols, such as THP and TCHP, which are used to treat HER2+ IBC. These protocols are associated with TRYPHAENA and have implications for patient treatment. [Data: Entities (167, 170), Relationships (187, 219)]\"\n        },\n        {\n            \"summary\": \"Authors and cardiac safety studies\",\n            \"explanation\": \"The community includes authors such as Chia, Eniu, Harvey, Hickish, Schneeweiss, and Waldron-Lynch, who have contributed to cardiac safety studies related to HER2+ IBC. These studies have implications for patient treatment and outcomes. [Data: Entities (700, 703, 702, 701, 699, 704), Relationships (214, 217, 216, 215, 213, 218)]\"\n        },\n        {\n            \"summary\": \"TRYPHAENA's relationship with cardiac safety studies\",\n            \"explanation\": \"TRYPHAENA is a randomized phase II cardiac safety study, which has implications for patient treatment and outcomes. The study's findings are associated with the authors and chemotherapy treatment protocols mentioned above. [Data: Entities (166), Relationships (214, 217, 216, 215, 213, 218)]\"\n        }\n    ]\n}", "input": "\nYou are an AI assistant that helps a human analyst to perform general information discovery. Information discovery is the process of identifying and assessing relevant information associated with certain entities (e.g., organizations and individuals) within a network.\n\n# Goal\nWrite a comprehensive report of a community, given a list of entities that belong to the community as well as their relationships and optional associated claims. The report will be used to inform decision-makers about information associated with the community and their potential impact. The content of this report includes an overview of the community's key entities, their legal compliance, technical capabilities, reputation, and noteworthy claims.\n\n# Report Structure\n\nThe report should include the following sections:\n\n- TITLE: community's name that represents its key entities - title should be short but specific. When possible, include representative named entities in the title.\n- SUMMARY: An executive summary of the community's overall structure, how its entities are related to each other, and significant information associated with its entities.\n- IMPACT SEVERITY RATING: a float score between 0-10 that represents the severity of IMPACT posed by entities within the community.  IMPACT is the scored importance of a community.\n- RATING EXPLANATION: Give a single sentence explanation of the IMPACT severity rating.\n- DETAILED FINDINGS: A list of 5-10 key insights about the community. Each insight should have a short summary followed by multiple paragraphs of explanatory text grounded according to the grounding rules below. Be comprehensive.\n\nReturn output as a well-formed JSON-formatted string with the following format:\n    {{\n        \"title\": <report_title>,\n        \"summary\": <executive_summary>,\n        \"rating\": <impact_severity_rating>,\n        \"rating_explanation\": <rating_explanation>,\n        \"findings\": [\n            {{\n                \"summary\":<insight_1_summary>,\n                \"explanation\": <insight_1_explanation>\n            }},\n            {{\n                \"summary\":<insight_2_summary>,\n                \"explanation\": <insight_2_explanation>\n            }}\n        ]\n    }}\n\n# Grounding Rules\n\nPoints supported by data should list their data references as follows:\n\n\"This is an example sentence supported by multiple data references [Data: <dataset name> (record ids); <dataset name> (record ids)].\"\n\nDo not list more than 5 record ids in a single reference. Instead, list the top 5 most relevant record ids and add \"+more\" to indicate that there are more.\n\nFor example:\n\"Person X is the owner of Company Y and subject to many allegations of wrongdoing [Data: Reports (1), Entities (5, 7); Relationships (23); Claims (7, 2, 34, 64, 46, +more)].\"\n\nwhere 1, 5, 7, 23, 2, 34, 46, and 64 represent the id (not the index) of the relevant data record.\n\nDo not include information where the supporting evidence for it is not provided.\n\n\n# Example Input\n-----------\nText:\n\nEntities\n\nid,entity,description\n5,VERDANT OASIS PLAZA,Verdant Oasis Plaza is the location of the Unity March\n6,HARMONY ASSEMBLY,Harmony Assembly is an organization that is holding a march at Verdant Oasis Plaza\n\nRelationships\n\nid,source,target,description\n37,VERDANT OASIS PLAZA,UNITY MARCH,Verdant Oasis Plaza is the location of the Unity March\n38,VERDANT OASIS PLAZA,HARMONY ASSEMBLY,Harmony Assembly is holding a march at Verdant Oasis Plaza\n39,VERDANT OASIS PLAZA,UNITY MARCH,The Unity March is taking place at Verdant Oasis Plaza\n40,VERDANT OASIS PLAZA,TRIBUNE SPOTLIGHT,Tribune Spotlight is reporting on the Unity march taking place at Verdant Oasis Plaza\n41,VERDANT OASIS PLAZA,BAILEY ASADI,Bailey Asadi is speaking at Verdant Oasis Plaza about the march\n43,HARMONY ASSEMBLY,UNITY MARCH,Harmony Assembly is organizing the Unity March\n\nOutput:\n{{\n    \"title\": \"Verdant Oasis Plaza and Unity March\",\n    \"summary\": \"The community revolves around the Verdant Oasis Plaza, which is the location of the Unity March. The plaza has relationships with the Harmony Assembly, Unity March, and Tribune Spotlight, all of which are associated with the march event.\",\n    \"rating\": 5.0,\n    \"rating_explanation\": \"The impact severity rating is moderate due to the potential for unrest or conflict during the Unity March.\",\n    \"findings\": [\n        {{\n            \"summary\": \"Verdant Oasis Plaza as the central location\",\n            \"explanation\": \"Verdant Oasis Plaza is the central entity in this community, serving as the location for the Unity March. This plaza is the common link between all other entities, suggesting its significance in the community. The plaza's association with the march could potentially lead to issues such as public disorder or conflict, depending on the nature of the march and the reactions it provokes. [Data: Entities (5), Relationships (37, 38, 39, 40, 41,+more)]\"\n        }},\n        {{\n            \"summary\": \"Harmony Assembly's role in the community\",\n            \"explanation\": \"Harmony Assembly is another key entity in this community, being the organizer of the march at Verdant Oasis Plaza. The nature of Harmony Assembly and its march could be a potential source of threat, depending on their objectives and the reactions they provoke. The relationship between Harmony Assembly and the plaza is crucial in understanding the dynamics of this community. [Data: Entities(6), Relationships (38, 43)]\"\n        }},\n        {{\n            \"summary\": \"Unity March as a significant event\",\n            \"explanation\": \"The Unity March is a significant event taking place at Verdant Oasis Plaza. This event is a key factor in the community's dynamics and could be a potential source of threat, depending on the nature of the march and the reactions it provokes. The relationship between the march and the plaza is crucial in understanding the dynamics of this community. [Data: Relationships (39)]\"\n        }},\n        {{\n            \"summary\": \"Role of Tribune Spotlight\",\n            \"explanation\": \"Tribune Spotlight is reporting on the Unity March taking place in Verdant Oasis Plaza. This suggests that the event has attracted media attention, which could amplify its impact on the community. The role of Tribune Spotlight could be significant in shaping public perception of the event and the entities involved. [Data: Relationships (40)]\"\n        }}\n    ]\n}}\n\n\n# Real Data\n\nUse the following text for your answer. Do not make anything up in your answer.\n\nText:\n-----Entities-----\nhuman_readable_id,title,description,degree\r\n166,\"\"\"TRYPHAENA\"\"\",\"Here is a comprehensive summary of the data:\n\nTRYPHAENA is a clinical trial that investigated the safety and tolerability of dual anti-HER2 antibodies with different regimens. Specifically, it was a randomized phase 2 study that evaluated the safety and tolerability of dual anti-HER2 antibodies combined with NAC (Neoadjuvant chemotherapy). Additionally, TRYPHAENA was also a randomized phase II cardiac safety study. The study reported pCR (Pathological Complete Response) rates, DFS (Disease-Free Survival), and OS (Overall Survival) at the 3-year follow-up.\",10\r\n167,\"\"\"THP\"\"\",\"Here is a comprehensive summary of the data:\n\nTHP is a chemotherapy treatment protocol specifically designed for treating HER2+ Inflammatory Breast Cancer (IBC). It is a regimen that combines docetaxel, trastuzumab, and pertuzumab, which are used together to treat cancer. This treatment protocol was part of the NeoSphere clinical trial, which reported promising pathological complete response (pCR) rates.\",3\r\n170,\"\"\"TCHP\"\"\",\"Here is a comprehensive summary of the data:\n\nTCHP is a chemotherapy treatment protocol specifically designed for treating HER2+ Inflammatory Breast Cancer (IBC). It is a regimen that combines docetaxel, carboplatin, pertuzumab, and trastuzumab to provide effective treatment for patients with this type of cancer.\",2\r\n700,\"\"\"CHIA\"\"\",\"\"\"Chia is an author of a study on cardiac safety in patients with HER2-positive early breast cancer.\"\"\",1\r\n703,\"\"\"ENIU\"\"\",\"\"\"Eniu is an author of a study on cardiac safety in patients with HER2-positive early breast cancer.\"\"\",1\r\n702,\"\"\"HARVEY\"\"\",\"\"\"Harvey is an author of a study on cardiac safety in patients with HER2-positive early breast cancer.\"\"\",1\r\n701,\"\"\"HICKISH\"\"\",\"\"\"Hickish is an author of a study on cardiac safety in patients with HER2-positive early breast cancer.\"\"\",1\r\n699,\"\"\"SCHNEEWEISS\"\"\",\"\"\"Schneeweiss is an author of a study on cardiac safety in patients with HER2-positive early breast cancer.\"\"\",1\r\n704,\"\"\"WALDRON-LYNCH\"\"\",\"\"\"Waldron-Lynch is an author of a study on cardiac safety in patients with HER2-positive early breast cancer.\"\"\",1\r\n\n\n-----Relationships-----\nhuman_readable_id,source,target,description,rank\r\n212,\"\"\"TRYPHAENA\"\"\",\"\"\"OVERMOYER ET AL.\"\"\",\"\"\"Overmoyer et al. reported the results of the TRYPHAENA study, which investigated the efficacy of a neoadjuvant treatment for IBC patients.\"\"\",15\r\n210,\"\"\"TRYPHAENA\"\"\",\"\"\"THP\"\"\",\"\"\"TRYPHAENA evaluated the safety and tolerability of FEC regimen plus pertuzumab and trastuzumab followed by THP.\"\"\",13\r\n209,\"\"\"TRYPHAENA\"\"\",\"\"\"FEC REGIMEN\"\"\",\"\"\"TRYPHAENA evaluated the safety and tolerability of FEC regimen plus pertuzumab and trastuzumab followed by THP.\"\"\",13\r\n211,\"\"\"TRYPHAENA\"\"\",\"\"\"TCHP\"\"\",\"\"\"TRYPHAENA evaluated the safety and tolerability of docetaxel and carboplatin plus pertuzumab and trastuzumab (TCHP).\"\"\",12\r\n214,\"\"\"TRYPHAENA\"\"\",\"\"\"CHIA\"\"\",\"\"\"Chia is an author of the TRYPHAENA study, which is a randomized phase II cardiac safety study.\"\"\",11\r\n217,\"\"\"TRYPHAENA\"\"\",\"\"\"ENIU\"\"\",\"\"\"Eniu is an author of the TRYPHAENA study, which is a randomized phase II cardiac safety study.\"\"\",11\r\n216,\"\"\"TRYPHAENA\"\"\",\"\"\"HARVEY\"\"\",\"\"\"Harvey is an author of the TRYPHAENA study, which is a randomized phase II cardiac safety study.\"\"\",11\r\n215,\"\"\"TRYPHAENA\"\"\",\"\"\"HICKISH\"\"\",\"\"\"Hickish is an author of the TRYPHAENA study, which is a randomized phase II cardiac safety study.\"\"\",11\r\n213,\"\"\"TRYPHAENA\"\"\",\"\"\"SCHNEEWEISS\"\"\",\"\"\"Schneeweiss is an author of the TRYPHAENA study, which is a randomized phase II cardiac safety study.\"\"\",11\r\n218,\"\"\"TRYPHAENA\"\"\",\"\"\"WALDRON-LYNCH\"\"\",\"\"\"Waldron-Lynch is an author of the TRYPHAENA study, which is a randomized phase II cardiac safety study.\"\"\",11\r\n187,\"\"\"AC\"\"\",\"\"\"THP\"\"\",\"\"\"AC and THP are regimens used in cancer treatment.\"\"\",6\r\n219,\"\"\"THP\"\"\",\"\"\"TCHP\"\"\",\"\"\"THP and TCHP are regimens used in cancer treatment.\"\"\",5\r\n\n\nThe report should include the following sections:\n\n- TITLE: community's name that represents its key entities - title should be short but specific. When possible, include representative named entities in the title.\n- SUMMARY: An executive summary of the community's overall structure, how its entities are related to each other, and significant information associated with its entities.\n- IMPACT SEVERITY RATING: a float score between 0-10 that represents the severity of IMPACT posed by entities within the community.  IMPACT is the scored importance of a community.\n- RATING EXPLANATION: Give a single sentence explanation of the IMPACT severity rating.\n- DETAILED FINDINGS: A list of 5-10 key insights about the community. Each insight should have a short summary followed by multiple paragraphs of explanatory text grounded according to the grounding rules below. Be comprehensive.\n\nReturn output as a well-formed JSON-formatted string with the following format:\n    {{\n        \"title\": <report_title>,\n        \"summary\": <executive_summary>,\n        \"rating\": <impact_severity_rating>,\n        \"rating_explanation\": <rating_explanation>,\n        \"findings\": [\n            {{\n                \"summary\":<insight_1_summary>,\n                \"explanation\": <insight_1_explanation>\n            }},\n            {{\n                \"summary\":<insight_2_summary>,\n                \"explanation\": <insight_2_explanation>\n            }}\n        ]\n    }}\n\n# Grounding Rules\n\nPoints supported by data should list their data references as follows:\n\n\"This is an example sentence supported by multiple data references [Data: <dataset name> (record ids); <dataset name> (record ids)].\"\n\nDo not list more than 5 record ids in a single reference. Instead, list the top 5 most relevant record ids and add \"+more\" to indicate that there are more.\n\nFor example:\n\"Person X is the owner of Company Y and subject to many allegations of wrongdoing [Data: Reports (1), Entities (5, 7); Relationships (23); Claims (7, 2, 34, 64, 46, +more)].\"\n\nwhere 1, 5, 7, 23, 2, 34, 46, and 64 represent the id (not the index) of the relevant data record.\n\nDo not include information where the supporting evidence for it is not provided.\n\nOutput:", "parameters": {"model": "llama3-8b-8192", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 2000, "n": null}}